Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026)

Aytu Biopharma (AYTU) has reported Income from Continuing Operations for 17 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 242.59% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$30.8 million, a 562.35% decrease from a year earlier, with the FY2025 full-year figure at -$10.8 million, down 32.31% from the prior year.
• Income from Continuing Operations was -$5.6 million for Q1 2026 at Aytu Biopharma, up from -$10.6 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $7.0 million in Q2 2022 and troughed at -$53.3 million in Q1 2022.
• A 5-year average of -$5.5 million and a median of -$701000.0 in 2022 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 272.2% in 2025, down 1854.61% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$6.7 million in 2022, then jumped by 108.95% to $599000.0 in 2023, then gained by 13.86% to $682000.0 in 2024, then slumped by 1651.91% to -$10.6 million in 2025, then surged by 46.92% to -$5.6 million in 2026.
• The last three Income from Continuing Operations figures came in at -$5.6 million (Q1 2026), -$10.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.